查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837052

短肠症候群市场按治疗类型、产品类型、给药途径、最终用途、患者年龄和病因划分－2025-2032 年全球预测

Short Bowel Syndrome Market by Treatment Type, Product Type, Route Of Administration, End Use, Patient Age, Etiology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，短肠症候群市场规模将成长至 41.1406 亿美元，复合年增长率为 19.84%。

主要市场统计数据
基准年2024年 9.6642亿美元
预计2025年 11.6059亿美元
预测年份：2032年 4,114,060,000美元
复合年增长率（%） 19.84%

简要概述影响肠衰竭患者护理的多方面临床、后勤和治疗动态

短肠症候群是一项复杂的多学科临床挑战，需要协调一致的护理模式、创新的治疗方法以及灵活的供应链。患者的肠道功能受损程度各不相同，需要个别化地结合口服补液盐、肠外营养、药物治疗，有时还需要手术介入。每种治疗途径都有不同的后勤需求和临床终点，而最近的进展正在将重点从单纯维持生命转移到恢復生活品质并减少对肠外营养的长期依赖。

随着向社区和居家护理的转变持续推进，临床团队、支付方和製造商必须协调专科医院干预措施与可扩展门诊解决方案之间的矛盾。这种转变凸显了整合营养管理、药物优化和手术决策的综合护理计划的重要性。此外，生物製药和设备辅助手术的创新正在改变临床对话，促使医疗系统重新评估临床通讯协定、培训需求和基础设施投资。因此，相关人员必须以创新的方式，在治疗效果、医疗服务物流和以病人为中心的治疗结果之间寻求平衡。

治疗创新、分散式医疗服务和供应链弹性如何重新定义短肠症候群管理

在治疗方法创新、医疗分散化和监管预期不断变化等因素的推动下，短肠症候群格局正在转变。在治疗方面，标靶药物药物的出现重新定义了治疗目标，鼓励临床医生进行肠道康復，减少对肠外营养的依赖，而不是无限期地依赖支持性治疗。外科手术创新不断推进，肠道延长手术更加复杂，移植途径更加协调，这些都为患者拓展了治疗选择，并挑战了传统的治疗流程。

同时，长期营养照护朝向居家和门诊环境的转变，促使人们更加重视可靠的供应链、病患训练和远端监控能力。远端医疗支援的临床追踪和数位依从性工具正成为护理计画不可或缺的一部分，从而能够更早进行干预并更有效率地利用资源。从市场角度来看，製造商和服务供应商正在推出差异化的产品系列，将营养配方、辅助性治疗和设备支援相结合。因此，竞争优势取决于跨职能部门的编配，将临床效益与可扩展的交付模式和强大的支援服务相结合。

评估近期关税行动对短肠症候群生态系统的供应安全、临床连续性和商业策略的连锁反应

对进口医疗用品和原材料征收新关税，给整个短肠症候群护理生态系统带来了明显的压力，影响了製造商、经销商和供应商。胺基酸混合物、脂肪乳剂和专用肠内配方等关键成分的供应链遍布复杂的全球网络。对这些投入品征收关税增加了采购的复杂性，迫使製造商重新评估筹资策略。为此，企业正在多元化其供应商基础，增加库存缓衝，并在可能的情况下转向国产投入品，以减少国际贸易摩擦的风险。

然而，这些调整会对下游产生影响。医院和家庭输液服务提供者必须在采购的波动性与临床对稳定产品供应的需求之间取得平衡，这需要与供应商密切合作并严格审查紧急时应对计画。临床医生可能会观察到产品替代和配方可用性方面存在更大的差异，需要谨慎管理以保持临床的连续性。此外，关税可能会增加进口临床实验药物和医疗设备组件的直接成本，从而影响临床试验和商业上市的经济效益，并可能延迟申办方的决策并延长上市时间。

製造商优先考虑供应链的弹性和成本效率，服务供应商正在投资物流能力和供应商伙伴关係，而临床网路则在采购受限的情况下优先考虑医疗服务的连续性。这些转变凸显了主动的贸易风险管理和协作合约架构对于保障病患获得医疗服务并维持医疗服务的一致性的重要性。

全面剖析决定短肠症候群治疗需求和商业性定位的临床、产品、途径、环境、年龄和病因部分

了解细分的细微差别，可以揭示临床需求、产品设计和护理环境如何交织，共同塑造竞争和临床路径。在分析治疗类型时，我们会关注口服补充剂、肠外营养、药物治疗和外科干预，并将口服补充剂细分为营养补充剂和营养配方，肠外营养细分为定製配方和标准化配方，药物治疗细分为抗生素、生长因子和激素，外科干预细分为肠移植和肠道延长手术。这种基于治疗的细分凸显了不同的需求驱动因素，有些患者依赖药物来增强吸收，有些患者需要透过定製或标准化解决方案获得长期肠外支持，还有一部分患者需要手术復原。

按产品类型划分，市场包括辅助性治疗、肠外营养、药物製剂和肠外营养解决方案。辅助性治疗也包括益生菌、维生素和矿物质；肠内製剂分为元素製剂、聚合物製剂和半元素製剂；药物製剂以替度鲁肽等药物为主；肠外营养包括胺基酸溶液、碳水化合物溶液和脂肪乳化。该产品特定图谱突显了临床差异化、製剂科学和监管途径的交汇点，展现了製剂优化和支持性护理商品搭售的机会。

给药途径是另一个关键维度，静脉注射和口服给药决定了设备需求、病患教育要求和监测强度。居家照护强调培训、远端监控和物流；医院优先考虑急性护理和复杂的外科手术；专科诊所强调多学科復健和长期追踪。将患者年龄分层为成人、老年和儿童组可以揭示不同的生理需求、剂量和看护者动态，而基于病因的细分（先天性疾病、克隆氏症、肠系膜缺血）则显示出疾病轨迹和治疗意图的异质性。这些相交的细分框架为产品设计、临床试验人群、报销策略和通路开发提供信息，使相关人员能够将投资组合策略与精确的临床和运营要求相结合。

医疗保健基础设施、报销环境和医疗保健提供者能力的地区差异如何影响全球短肠症候群市场的准入和采用

全球短肠症候群市场的区域动态显着影响着临床实务模式、监管格局和商业策略。在美洲，完善的家庭输液基础设施和成熟的报销途径支持先进的营养疗法，并促进了药物在肠道復健中的应用。该地区的相关人员正优先考虑与慢性病照护模式的整合，并增加对病患教育和远端监控的投资，以减少对医院的依赖并改善长期疗效。

欧洲、中东和非洲各地的医疗体系提供先进治疗药物和专科外科服务的可近性水准参差不齐，因此需要采取差异化的市场策略。虽然重症监护仍然是该地区多个市场复杂干预措施的主导模式，但人们对门诊病人营养管理日益增长的兴趣为基于社区的生产和定制的经销伙伴提供了机会。不同的政策和监管差异需要製定细緻的打入市场策略，以适应每个国家的报销框架和临床指南。

亚太地区医疗基础设施发展迅速，但人口结构差异较大，既带来了挑战，也带来了机会。该地区的都市区越来越多地采用先进的药物和外科解决方案，而资源受限的环境则优先考虑扩充性的肠内和肠外治疗策略。製造商和服务供应商的成功取决于灵活的产品系列、与本地经销商的合作伙伴关係关係，以及对临床医生教育的投资，以弥合医疗服务提供方面的差距，并扩大不同医疗保健体系之间的医疗服务可及性。

了解策略伙伴关係、配方专业化和综合护理能力如何决定短肠症候群的竞争优势

短肠症候群领域的竞争态势体现了大型製药企业和营养公司、特殊生物製药开发商以及管理复杂输液和居家照护服务的服务供应商的混合格局。主要企业专注于透过投资专有配方、以临床医生为中心的教育计画以及确保关键肠外和肠内产品一致性的供应链来打造明显的差异化。同时，专业的创新者则透过开发针对肠道适应症的标靶药物配方或与临床中心合作以产生改变实践的证据来追求利基优势。

战略伙伴关係已成为加速市场进入和扩大规模的热门途径。透过汇集配方和物流专家，他们可以弥合产品创新与可靠的现场交付之间的差距。此外，企业正增加对数位护理平台的投资，这些平台透过实现远端患者监护、依从性追踪、简化输液管理等功能，与其核心产品形成互补。产品、服务和数位工具的融合创造了一种竞争格局，支付方和医疗服务提供者都在寻求能够减轻看护者负担并显着改善患者治疗效果的综合解决方案。企业必须在研发投资与製造弹性、法规遵循以及向不同相关人员传达价值等务实考量之间取得平衡。

製造商、医疗保健提供者和付款人的策略和营运重点是保护患者的治疗机会并加快治疗结果

产业领导者应将短期营运改善与长期策略投资结合，以巩固自身地位并改善病患治疗效果。首先，优先考虑供应链多元化和关键投入（例如胺基酸、脂肪乳剂和特殊肠内成分）的双重采购，以降低关税和贸易风险，并支持不间断的临床交付。同时，投资强大的居家照护支援项目，包括标准化培训课程、远端监控技术和药剂师主导的药物管理，以提高住院过渡期间的安全性和依从性。

其次，我们将专注于研发能够引起支付方和医疗服务提供者共鸣的临床终点，透过收集减少肠外依赖、降低住院率以及患者报告生活品质的证据。在可能的情况下，我们将进行务实的研究和现实世界证据倡议，以证明跨病因和跨年龄层的多学科治疗方法的有效性。第三，我们将与专科诊所和多学科中心建立伙伴关係，简化可能受益于手术方案、生长因子和肠道復健服务的患者治疗途径，并确保优化转诊网络和护理协调机制。

最后，发展灵活的商业模式，解决当地的报销现实问题，并支援捆绑合同，以实现综合服务和产品交付。透过结合营运弹性、循证开发、临床伙伴关係和适应性强的市场开发方法，领导者可以提供更可预测和改进的病人历程，同时保持竞争优势。

结合临床医生参与、文献综合和营运审查的严格多方法研究途径检验了临床和商业性见解

调查方法采用多方法论，将初步质性研究与严谨的二次分析结合，以整体情况短肠症候群。主要方法包括与胃肠病学、外科、营养学和家庭输液服务领域的临床医生进行深入访谈，以及与供应链经理和付款人代表进行结构化咨询，以了解营运限制和报销驱动因素。此外，还与关键意见领袖举行了顾问小组会议，以检验临床路径并确定不同患者群体中未满足的需求。

二级资讯来源包括同行评审的临床文献、监管通知、临床试验註册中心和公共卫生指南，以绘製治疗机制、安全性概况和护理实践标准。此外，还分析了产品标籤、生产指南文件和通路，以评估配方的复杂性和物流要求。数据品质程序包括跨多个资讯来源的三角测量、与临床指南的一致性以及与临床专家的迭代检验，以确保结论反映当前的实践和营运现状。在整个过程中，我们将见解按治疗类型、产品类别、给药途径、护理环境、患者年龄和疾病病因进行分类，以保持分析的精细度和实际相关性。

专注于临床创新、营运弹性和伙伴关係关係的策略整合将决定未来的有效性和可近性

短肠症候群既带来了持续的挑战，也带来了新的机会，需要临床医生、製造商、付款者和服务提供者的协调应对。药物和外科技术的进步扩大了治疗的可能性，而向家庭营养管理的转变则需要加强物流、病患教育和远端监控。贸易政策的变化和供应链中断进一步加剧了环境的复杂性，迫使各组织优先考虑具有韧性和适应性的筹资策略。

未来的永续发展将取决于将证据生成与以患者为中心的实用交付模式相结合。相关人员若能将临床创新与卓越营运相结合，在整个医疗照护过程中建立伙伴关係，并向付款人传达清晰的价值提案，将最有可能改善患者轨迹并创造可持续的商业性优势。在此背景下，将临床细节与医疗服务实际结合的可操作情报将成为策略决策和有效专案执行的关键输入。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 类升糖素样胜肽-2类似物疗法的出现扩大了短肠症候群的治疗选择
  • 肠道延长手术技术的进步改善了成年患者的预后
  • 扩大居家肠外营养系统的采用可改善 SBS 患者的生活品质
  • 再生医学和组织工程中修復肠黏膜的新方法
  • 整合远端医疗服务进行营养管理，改善病患监测与遵从性
  • 人们对微生物组调节疗法的兴趣日益浓厚，以减少併发症并支持肠道适应
  • 不断变化的报销和定价策略正在影响整个全部区域获得专业 SBS 护理的机会

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章短肠症候群市场（依治疗类型）

  • 口服补充剂
    • 营养补充品
    • 营养配方
  • 静脉营养
    • 客製化PN
    • 标准 PN
  • 药物治疗
    • 抗生素
    • 生长因子
    • 荷尔蒙
  • 外科手术干预
    • 肠道移植
    • 肠道延长手术

第九章短肠症候群市场（依产品类型）

  • 辅助性治疗
    • 益生菌
    • 维生素和矿物质
  • 经肠营养
    • 元素膳食补充剂
    • 消化营养补充品
    • 半消化营养补充品
  • 药理
    • 替度鲁肽
  • PN解决方案
    • 胺基酸溶液
    • 碳水化合物解决方案
    • 脂肪乳剂

短肠症候群市场（依给药途径）

  • 静脉
  • 口服

第 11 章短肠症候群市场：依最终用途

  • 居家护理设施
  • 医院
  • 专科诊所

第 12 章短肠症候群市场（依病患年龄）

  • 成人
  • 老年人
  • 孩子们

第十三章短肠症候群市场：依病因

  • 先天性疾病
  • 克隆氏症
  • 肠繫膜缺血

第十四章短肠症候群市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 15 章短肠症候群市场：按组

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章短肠症候群市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Ajinomoto Co., Inc.
    • Terumo Corporation
    • Becton, Dickinson and Company
    • ICU Medical, Inc.
    • Smiths Medical（Smiths Group plc）
    • Otsuka Holdings Co., Ltd.
    • Lonza Group AG
    • CordenPharma International AG
    • Gland Pharma Limited
    • Hikma Pharmaceuticals PLC
Product Code: MRR-0309FBC51139

The Short Bowel Syndrome Market is projected to grow by USD 4,114.06 million at a CAGR of 19.84% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 966.42 million
Estimated Year [2025] USD 1,160.59 million
Forecast Year [2032] USD 4,114.06 million
CAGR (%) 19.84%

A concise overview of the multifaceted clinical, logistical, and therapeutic dynamics reshaping care for patients with intestinal failure

Short bowel syndrome represents a complex, multidisciplinary clinical challenge that demands coordinated care models, innovative therapeutics, and adaptive supply chains. Patients experience variable intestinal function losses that necessitate individualized combinations of oral supplementation, parenteral nutrition, pharmacological therapy, and sometimes surgical intervention. Each therapeutic pathway carries distinct logistical requirements and clinical endpoints, and recent advances have shifted the emphasis from merely sustaining life to restoring quality of life and reducing long-term dependence on parenteral support.

As care moves increasingly into community and home settings, clinical teams, payers, and manufacturers must reconcile the tension between specialized hospital-based interventions and scalable outpatient solutions. This dynamic elevates the importance of integrated care plans that connect nutritional management, pharmacologic optimization, and surgical decision-making. Moreover, innovations in biological agents and device-assisted procedures are altering the clinical conversation, prompting health systems to reassess clinical protocols, training needs, and infrastructure investments. Consequently, stakeholders must navigate a landscape where therapeutic efficacy, delivery logistics, and patient-centered outcomes intersect in novel ways.

How innovation in therapeutics, decentralization of care delivery, and supply chain resilience are collectively redefining short bowel syndrome management

The short bowel syndrome landscape is undergoing transformative shifts driven by therapeutic innovation, decentralization of care, and evolving regulatory expectations. On the therapeutic front, the emergence of targeted pharmacologic agents has redefined treatment goals, encouraging clinicians to pursue intestinal rehabilitation and reduction of parenteral dependence rather than indefinite support. Surgical innovation continues to progress with refined intestinal lengthening techniques and more coordinated transplant pathways, which collectively expand patient options and challenge traditional care algorithms.

Simultaneously, the migration of long-term nutritional management into the home and outpatient settings has intensified focus on reliable supply chains, patient training, and remote monitoring capabilities. Telehealth-enabled clinical follow-up and digital adherence tools are becoming integral to care plans, enabling earlier interventions and more efficient resource utilization. From a market perspective, manufacturers and service providers are responding with differentiated product portfolios that combine nutritional formulations, adjunctive therapies, and device-enabled support, while payers increasingly demand evidence of real-world outcomes and cost-effectiveness. As a result, competitive advantage now hinges on cross-functional orchestration that aligns clinical benefit with scalable delivery models and robust support services.

Evaluating the ripple effects of recent tariff actions on supply security, clinical continuity, and commercial strategies within the short bowel syndrome ecosystem

The imposition of new tariffs on imported medical goods and raw materials has created palpable stress across the short bowel syndrome care ecosystem, affecting manufacturers, distributors, and providers. Supply lines for critical components such as amino acid blends, lipid emulsions, and specialized enteral formulas traverse complex global networks; tariffs on these inputs increase procurement complexity and compel manufacturers to reassess sourcing strategies. In response, organizations are diversifying supplier bases, increasing inventory buffers, and, where feasible, shifting toward domestically produced inputs to reduce exposure to international trade friction.

These adjustments, however, carry downstream effects. Hospitals and home infusion providers must reconcile procurement variability with the clinical necessity for consistent product availability, prompting closer collaboration with suppliers and heightened scrutiny of contingency planning. Clinicians may observe greater variability in product substitution and formulation availability, requiring careful management to preserve clinical continuity. Moreover, tariffs influence the economics of clinical trials and commercial launches by raising the direct cost of imported investigational materials and device components, which can slow sponsor decision-making and extend timelines for market entry.

In aggregate, the tariff environment accelerates strategic realignment across the value chain: manufacturers prioritize supply chain resilience and cost-efficiency, service providers invest in logistics capabilities and supplier partnerships, and clinical networks emphasize therapeutic continuity under constrained procurement conditions. These shifts underscore the importance of proactive trade-risk management and collaborative contracting frameworks to safeguard patient access and maintain therapeutic consistency.

A comprehensive dissection of clinical, product, route, setting, age, and etiology segments that determines therapeutic needs and commercial positioning for short bowel syndrome

A nuanced understanding of segmentation reveals how clinical need, product design, and care settings intersect to shape competition and clinical pathways. When analyzing treatment type, the landscape spans oral supplementation, parenteral nutrition, pharmacological therapy, and surgical intervention, where oral supplementation subdivides into dietary supplements and nutritional formulas, parenteral nutrition distinguishes customized and standard formulations, pharmacological therapy separates into antibiotics, growth factors, and hormonal agents, and surgical intervention includes bowel transplantation and intestinal lengthening procedures. This treatment-based segmentation highlights distinct demand drivers: some patients rely on pharmacologic agents to enhance absorptive capacity, others require long-term parenteral support with either bespoke or standardized solutions, and a subset proceed to surgical restoration efforts.

Looking through the lens of product type, the market encompasses adjunctive therapies, enteral formulas, pharmacologics, and parenteral nutrition solutions. Adjunctive therapies further include probiotics and vitamins and minerals, while enteral formulas are differentiated into elemental, polymeric, and semi-elemental variants; pharmacologics center on agents such as teduglutide, and parenteral solutions cover amino acid solutions, carbohydrate solutions, and lipid emulsions. This product-focused map clarifies where clinical differentiation, formulation science, and regulatory pathways converge, signaling opportunities for formulation optimization and supportive therapy bundling.

Route of administration provides another critical axis, with intravenous and oral pathways dictating device needs, patient education requirements, and monitoring intensity. End-use segmentation across home care facilities, hospitals, and specialty clinics underscores the operational implications of each treatment pathway: home care emphasizes training, remote monitoring, and logistics; hospitals prioritize acute management and complex surgical interventions; specialty clinics focus on multidisciplinary rehabilitation and longitudinal follow-up. Patient age stratification into adult, geriatric, and pediatric cohorts reveals differing physiologic needs, dosing considerations, and caregiver dynamics, while etiology-based segments-congenital conditions, Crohn disease, and mesenteric ischemia-demonstrate heterogeneity in disease trajectory and therapeutic intent. Together, these intersecting segmentation frameworks inform product design, clinical trial populations, reimbursement strategies, and channel development, enabling stakeholders to align portfolio strategies with precise clinical and operational requirements.

How distinct regional healthcare infrastructures, reimbursement environments, and provider capabilities shape access and adoption across global short bowel syndrome markets

Regional dynamics exert a powerful influence on clinical practice patterns, regulatory expectations, and commercial strategies across the global short bowel syndrome landscape. In the Americas, established home infusion infrastructures and mature reimbursement pathways support advanced nutritional therapies and facilitate adoption of pharmacologic agents aimed at intestinal rehabilitation. Stakeholders in this region emphasize integration with chronic care models and investment in patient education and remote monitoring to reduce hospital reliance and improve long-term outcomes.

Across Europe, the Middle East & Africa, health systems exhibit varied levels of access to advanced therapeutics and specialized surgical services, necessitating differentiated market approaches. In several markets within this region, centralized hospital care remains the dominant model for complex interventions, while growing interest in outpatient nutritional management presents opportunities for localized manufacturing and tailored distribution partnerships. Policy heterogeneity and regulatory divergence require nuanced market access strategies that accommodate national reimbursement frameworks and clinical guidelines.

The Asia-Pacific region combines rapidly developing healthcare infrastructure with high population heterogeneity, creating both challenges and opportunities. Urban centers in this region increasingly adopt advanced pharmacologic and surgical solutions, while resource-constrained settings prioritize scalable enteral and parenteral strategies. For manufacturers and service providers, success depends on flexible product portfolios, collaborative partnerships with local distributors, and investments in clinician education to bridge gaps in care delivery and expand appropriate access across diverse healthcare systems.

Insights into how strategic partnerships, formulation specialization, and integrated care capabilities determine competitive advantage in short bowel syndrome

Competitive dynamics in the short bowel syndrome domain reflect a blend of large pharmaceutical and nutrition firms, specialty biologic developers, and service providers that manage complex infusion and home care delivery. Leading companies concentrate on charting clear differentiation through proprietary formulations, clinician-focused education programs, and supply chain investments that ensure consistency of critical parenteral and enteral products. At the same time, specialized innovators pursue niche advantages by developing targeted pharmacologics that address intestinal adaptation and by partnering with clinical centers to generate practice-changing evidence.

Strategic partnerships have become a common pathway to accelerate market entry and scale; collaborations between formulation experts and logistics specialists help bridge gaps between product innovation and reliable in-field delivery. Additionally, a growing number of companies are investing in digital care platforms that complement core products, enabling remote patient monitoring, adherence tracking, and streamlined infusion management. This convergence of product, service, and digital tools fosters a competitive environment where integrated solutions that reduce caregiver burden and demonstrably improve patient outcomes command attention from payers and providers alike. To remain relevant, companies must balance investments in R&D with pragmatic attention to manufacturing resilience, regulatory navigation, and value communication to diverse stakeholders.

Actionable strategic and operational priorities that manufacturers, providers, and payers should implement to safeguard access and accelerate therapeutic impact for patients

Industry leaders should pursue a mix of immediate operational improvements and longer-term strategic investments to strengthen position and enhance patient outcomes. First, prioritize supply chain diversification and dual sourcing for critical inputs such as amino acids, lipid emulsions, and specialized enteral components to reduce tariff and trade exposure and to support uninterrupted clinical delivery. Concurrently, invest in robust home care enablement programs that include standardized training curricula, remote monitoring technologies, and pharmacist-led medication management to improve safety and adherence as care shifts away from inpatient settings.

Second, align R&D focus with clinical endpoints that resonate with payers and providers by generating evidence on reduced parenteral dependence, hospital readmissions, and patient-reported quality of life. Where possible, pursue pragmatic studies and real-world evidence initiatives that demonstrate the effectiveness of combined therapeutic approaches across different patient etiologies and age groups. Third, cultivate partnerships with specialty clinics and multidisciplinary centers to streamline pathways for patients who may benefit from surgical options, growth factors, or intestinal rehabilitation services, ensuring that referral networks and care coordination mechanisms are optimized.

Lastly, develop flexible commercial models that accommodate regional reimbursement realities and support bundled contracting for integrated service-product offerings. By combining operational resilience, evidence-driven development, clinical partnerships, and adaptable go-to-market approaches, leaders can sustain competitive advantage while delivering more predictable and improved patient journeys.

A rigorous multimethod research approach combining clinician engagement, literature synthesis, and operational review to validate clinical and commercial insights

The research methodology employed a multimodal approach that synthesizes primary qualitative insight with rigorous secondary analysis to develop a holistic view of the short bowel syndrome landscape. Primary methods included in-depth interviews with clinicians across gastroenterology, surgery, nutrition, and home infusion services, as well as structured consultations with supply chain managers and payer representatives to understand operational constraints and reimbursement drivers. These conversations were complemented by advisory-panel sessions with key opinion leaders to validate clinical pathways and identify unmet needs across different patient cohorts.

Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, clinical trial registries, and public health guidance to map therapeutic mechanisms, safety profiles, and standard-of-care practices. Additionally, product labeling, manufacturing guidance documents, and distribution channel analyses informed assessments of formulation complexity and logistical requirements. Data quality procedures included triangulation across multiple sources, consistency checks against clinical guidelines, and iterative validation with clinical experts to ensure that conclusions reflect current practice and operational realities. Throughout the process, care was taken to disaggregate insights across treatment types, product classes, routes of administration, care settings, patient ages, and etiologies to preserve analytical granularity and practical relevance.

A strategic synthesis of clinical innovation, operational resilience, and partnership-focused strategies that will determine future efficacy and access

Short bowel syndrome presents both persistent challenges and emerging opportunities that require coordinated responses from clinicians, manufacturers, payers, and service providers. Advances in pharmacologic agents and surgical techniques expand therapeutic possibilities, while the shift toward home-based nutritional management demands strengthened logistics, patient education, and remote monitoring. Trade policy changes and supply chain disruptions further complicate the environment, prompting organizations to prioritize resilience and adaptable sourcing strategies.

Moving forward, sustainable progress will depend on the ability to integrate evidence generation with practical delivery models that prioritize patient-centered outcomes. Stakeholders that align clinical innovation with operational excellence, cultivate partnerships across the care continuum, and communicate clear value propositions to payers will be best positioned to improve patient trajectories and create durable commercial advantage. In this context, actionable intelligence that bridges clinical nuance and real-world delivery mechanics becomes an essential input for strategic decision-making and effective program execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging glucagon-like peptide-2 analog therapies expanding treatment options for short bowel syndrome
  • 5.2. Advancements in intestinal lengthening surgical techniques improving patient outcomes in adults
  • 5.3. Growing adoption of home parenteral nutrition delivery systems enhancing quality of life in SBS patients
  • 5.4. Emerging regenerative medicine and tissue engineering approaches targeting intestinal mucosa restoration
  • 5.5. Integration of telehealth services for nutritional management improving patient monitoring and adherence
  • 5.6. Increasing focus on microbiome modulation therapies to reduce complications and support intestinal adaptation
  • 5.7. Evolving reimbursement and pricing strategies impacting access to specialized SBS treatments across regions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Short Bowel Syndrome Market, by Treatment Type

  • 8.1. Oral Supplementation
    • 8.1.1. Dietary Supplements
    • 8.1.2. Nutritional Formulas
  • 8.2. Parenteral Nutrition
    • 8.2.1. Customized Pn
    • 8.2.2. Standard Pn
  • 8.3. Pharmacological Therapy
    • 8.3.1. Antibiotics
    • 8.3.2. Growth Factors
    • 8.3.3. Hormonal Agents
  • 8.4. Surgical Intervention
    • 8.4.1. Bowel Transplantation
    • 8.4.2. Intestinal Lengthening Procedures

9. Short Bowel Syndrome Market, by Product Type

  • 9.1. Adjunctive Therapies
    • 9.1.1. Probiotics
    • 9.1.2. Vitamins And Minerals
  • 9.2. Enteral Formulas
    • 9.2.1. Elemental Formulas
    • 9.2.2. Polymeric Formulas
    • 9.2.3. Semi-elemental Formulas
  • 9.3. Pharmacologics
    • 9.3.1. Teduglutide
  • 9.4. Pn Solutions
    • 9.4.1. Amino Acid Solutions
    • 9.4.2. Carbohydrate Solutions
    • 9.4.3. Lipid Emulsions

10. Short Bowel Syndrome Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Short Bowel Syndrome Market, by End Use

  • 11.1. Home Care Facilities
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Short Bowel Syndrome Market, by Patient Age

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Short Bowel Syndrome Market, by Etiology

  • 13.1. Congenital Conditions
  • 13.2. Crohn Disease
  • 13.3. Mesenteric Ischemia

14. Short Bowel Syndrome Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Short Bowel Syndrome Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Short Bowel Syndrome Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Ajinomoto Co., Inc.
    • 17.3.2. Terumo Corporation
    • 17.3.3. Becton, Dickinson and Company
    • 17.3.4. ICU Medical, Inc.
    • 17.3.5. Smiths Medical (Smiths Group plc)
    • 17.3.6. Otsuka Holdings Co., Ltd.
    • 17.3.7. Lonza Group AG
    • 17.3.8. CordenPharma International AG
    • 17.3.9. Gland Pharma Limited
    • 17.3.10. Hikma Pharmaceuticals PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SHORT BOWEL SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA SHORT BOWEL SYNDROME MAR